Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy
{{output}}
Background and objectives: Pancreatic ductal adenocarcinoma (PDAC) is characterized by limited survival rates, yet patients who achieve optimal CA19-9 response to neoadjuvant therapy (NAT) exhibit improved survival. This study ex... ...
